News

The study in 60 patients with uncontrolled hypertension demonstrated that SLx-2101 caused clinically significant reductions in blood pressure and was well-tolerated. The trial was designed to examine the

Former CEO Nicholas Teti, Jr will continue to serve as chairman of the board of directors and as a consultant to the company, but has resigned as president

While most pharmacological agents are employed to chemically signal cells to interrupt, reduce production or bind and regulate specific disease-causing proteins, this application of Cytogenix’s novel single-stranded DNA

The study will evaluate the efficacy and safety of CTCE-9908 administered at a dose of 5mg/kg. The primary end point will be to determine the response rate of

According to the companies, the MilliPROBE system is the first solution of its kind for biopharmaceutical manufacturing. It combines Millipore’s sample prep methodologies with Gen-Probe’s advanced nucleic acid

Third Wave also announced that four well-known regional distributors have been secured to distribute its human papillomavirus (HPV) product in Italy. The company recently announced that its HPV

Enrollment for the program will begin in the first quarter of 2008 with an expected completion date in the second half of the year. CP404 is a calcium

Under the terms of the agreement, Biogen Idec and PDL have granted Ophthotech worldwide development and commercial rights to all ophthalmic uses of volociximab (M200). Biogen Idec and

Clirophtha is a contract research organization in Europe and North America that is dedicated to ophthalmology clinical trials. Iris Pharma said that this merger establishes the first global